K

Kyverna Therapeutics
D

KYTX

7.21000
USD
-0.06
(-0.82%)
قبل الجلسة·7.38000USD+0.17000(+2.36%)
حجم التداول
1,650
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
440,765,287
المقالات
المزيد

العنوان: Kyverna Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.